Publication
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.
Authors not recorded
Nat Commun2023PMID 37666855PMC10477267stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugCetuximabcivic_curation1.00
- drugFOLFIRI Regimencivic_curation1.00
- geneTOP1civic_curation1.00
- variantTOP1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37666855
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TOP1 Amplification1 | ||||||||
| Cetuximab + FOLFIRI RegimenCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12143The OncoBird framework utilizes data from the open-label, randomized phase III FIRE-3 trial, which involved patients with metastatic colorectal carcinoma who received either cetuximab or bevacizumab i… (full text at CIViC) PMID 37666855 · Ohnmacht et al., 2023 · Open in CIViC | civic |